Panitumumab CAS 339177-26-3
Introduction：Basic information about Panitumumab CAS 339177-26-3, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Panitumumab Basic information
| Product Name: | Panitumumab |
| Synonyms: | Panitumumab;Abx-egf;Abx-egf mab;Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal abx-egf heavy chain), disulfide with human monoclonal abx-egf light chain, dimer;Unii-6A901E312a;Vectibix;Abenix;Panitumumab USP/EP/BP |
| CAS: | 339177-26-3 |
| MF: | |
| MW: | 0 |
| EINECS: | |
| Product Categories: | |
| Mol File: | Mol File |
Panitumumab Chemical Properties
| storage temp. | Store at -20°C |
| form | Liquid |
| color | Colorless to light yellow |
Safety Information
| Description | Panitumumab is a recombinant, fully human IgG2 kappa monoclonal antibodythat is highly selective for the epidermal growth factor receptor (EGFR),and it is indicated for the treatment of EGFR-expressing, metastatic colorectalcarcinoma (mCRC) with disease progression on or following fluoropyrimidine-,oxaliplatin-, and irinotecan-containing chemotherapy regimens. Overexpressionof EGFR is detected in many human cancers, including those of the colon andrectum. Panitumumab blocks the binding of ligands such as epidermal growthfactor (EGF) and transforming growth factor (TGF-a) to various EGFR-expressingcell lines, which results in inhibition of EGF-dependent tumor cell activation,induction of apoptosis, and decreased pro-inflammatory cytokine and vasculargrowth factor production. In vitro, panitumumab binds EGFR with high affinity(KD ? 50pM; IC50 ? 3 nM) in human cervical epidermal cell line A-431.. |
| Originator | Abgenix (US) |
| Uses | Antineoplastic. |
| Brand name | Vectibix |
| Clinical Use | Monoclonal antibody: Treatment of metastatic colorectal cancer |
| Drug interactions | Potentially hazardous interactions with other drugs Cytotoxics: avoid with bevacizumab, fluorouracil, irinotecan and oxaliplatin. Folinic acid: avoid concomitant use. Live vaccines: avoid concomitant use. |
| Metabolism | Saturable elimination mediated via reticuloendothelial system, and internalisation and degradation of EGFR. |
Panitumumab Preparation Products And Raw materials
